Predictive Oncology (POAI) Competitors $0.87 +0.01 (+1.62%) As of 02:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock POAI vs. FEMY, VVOS, DRIO, RVP, PETV, IRIX, NXGL, ALUR, NRXS, and NXLShould you be buying Predictive Oncology stock or one of its competitors? The main competitors of Predictive Oncology include Femasys (FEMY), Vivos Therapeutics (VVOS), DarioHealth (DRIO), Retractable Technologies (RVP), PetVivo (PETV), IRIDEX (IRIX), NexGel (NXGL), Allurion Technologies (ALUR), NeurAxis (NRXS), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry. Predictive Oncology vs. Its Competitors Femasys Vivos Therapeutics DarioHealth Retractable Technologies PetVivo IRIDEX NexGel Allurion Technologies NeurAxis Nexalin Technology Predictive Oncology (NASDAQ:POAI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Does the media refer more to POAI or FEMY? In the previous week, Femasys had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 8 mentions for Femasys and 7 mentions for Predictive Oncology. Femasys' average media sentiment score of 0.28 beat Predictive Oncology's score of -0.16 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is POAI or FEMY more profitable? Predictive Oncology has a net margin of -587.31% compared to Femasys' net margin of -1,113.72%. Femasys' return on equity of -713.74% beat Predictive Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Predictive Oncology-587.31% -722.01% -167.23% Femasys -1,113.72%-713.74%-152.60% Do analysts recommend POAI or FEMY? Predictive Oncology currently has a consensus price target of $3.00, indicating a potential upside of 244.83%. Femasys has a consensus price target of $7.33, indicating a potential upside of 944.63%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Predictive Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in POAI or FEMY? 9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 3.4% of Predictive Oncology shares are owned by insiders. Comparatively, 11.5% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has higher valuation and earnings, POAI or FEMY? Predictive Oncology has higher earnings, but lower revenue than Femasys. Femasys is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPredictive Oncology$1.62M5.85-$12.66M-$3.05-0.29Femasys$1.63M14.03-$18.82M-$0.86-0.82 Which has more volatility & risk, POAI or FEMY? Predictive Oncology has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.58, meaning that its share price is 358% less volatile than the S&P 500. SummaryFemasys beats Predictive Oncology on 12 of the 16 factors compared between the two stocks. Get Predictive Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POAI vs. The Competition Export to ExcelMetricPredictive OncologyMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.47M$2.09B$5.72B$9.77BDividend YieldN/AN/A3.77%4.10%P/E Ratio-0.2937.1930.9025.26Price / Sales5.8510.13403.8188.28Price / CashN/A51.0625.2228.45Price / Book-29.0010.739.516.00Net Income-$12.66M-$63.67M$3.26B$265.34M7 Day Performance19.90%5.94%4.48%2.84%1 Month Performance10.13%2.62%5.19%1.58%1 Year Performance-0.57%28.46%31.75%25.40% Predictive Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POAIPredictive Oncology1.6064 of 5 stars$0.87+1.6%$3.00+244.8%-2.2%$9.47M$1.62M-0.2930Earnings ReportFEMYFemasys2.9678 of 5 stars$0.78-13.2%$7.33+845.7%-34.9%$29.04M$1.63M-0.9030Short Interest ↑Gap UpVVOSVivos Therapeutics1.5016 of 5 stars$4.58+4.1%$4.82+5.2%+76.4%$25.91M$15.03M-2.65160Upcoming EarningsDRIODarioHealth1.4628 of 5 stars$0.50-6.8%$2.00+297.6%-49.3%$24.57M$27.04M-0.90200RVPRetractable Technologies1.7258 of 5 stars$0.82+5.3%N/A-18.9%$24.43M$33.75M-1.51240Positive NewsShort Interest ↑Gap UpPETVPetVivoN/A$0.86-1.1%N/A+35.2%$23.68M$1.05M-1.9120IRIXIRIDEX1.2585 of 5 stars$1.26-3.1%N/A-40.2%$21.83M$48.67M-2.93120Earnings ReportNXGLNexGel1.3926 of 5 stars$2.65-1.5%N/A-6.9%$20.59M$8.69M-5.8910Earnings ReportShort Interest ↓ALURAllurion Technologies2.5419 of 5 stars$2.62-2.2%$22.83+771.5%-85.4%$19.99M$32.11M-0.21501Analyst DowngradeShort Interest ↓Gap UpNRXSNeurAxis2.8412 of 5 stars$2.43-1.2%$7.00+188.1%-24.2%$17.54M$2.93M-1.3219Short Interest ↑Gap UpNXLNexalin Technology3.102 of 5 stars$0.89-1.1%$5.00+461.8%-19.7%$15.68M$170K-1.173Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Femasys Competitors Vivos Therapeutics Competitors DarioHealth Competitors Retractable Technologies Competitors PetVivo Competitors IRIDEX Competitors NexGel Competitors Allurion Technologies Competitors NeurAxis Competitors Nexalin Technology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:POAI) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access